Thus, a standard Cr51‐release killing assay on parental (HLA‐Elow) and transfected (HLA‐Ehigh) CAL‐27 tumor cells confirmed that monalizumab enhanced NK‐cell killing, to a larger extent in the case of HLA‐E‐expressing tumors (Fig 7F). Here, HLA-E is linked to neoplasm.